Guselkumab for moderately to severely active ulcerative colitis

被引：0
|
作者：
不详
机构：
来源：
LANCET GASTROENTEROLOGY & HEPATOLOGY | 2025年 / 10卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：112 / 112
页数：1
相关论文
共 50 条
  • [31] Cost Per Clinical Outcomes With Biologics for the Treatment of Moderately to Severely Active Ulcerative Colitis
    Jansen, Jeroen P.
    Mody, Reema
    Patel, Haridarshan
    Lorenzi, Maria
    Ursan, Iulia
    Alberton, Mark
    GASTROENTEROLOGY, 2015, 148 (04) : S1 - S2
  • [32] Long-term use of ozanimod in patients with moderately to severely active Ulcerative Colitis
    Danese, S.
    Colombel, J. F.
    Ponich, T.
    Jovanovic, I.
    Bossuyt, P.
    Longman, R.
    Alekseeva, O.
    Petersen, A.
    Chitkara, D.
    Marta, C.
    Charles, L.
    Rubin, D. T.
    Afzali, A.
    Loftus, E. V.
    Wolf, D. C.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I093 - I094
  • [33] LONG-TERM USE OF OZANIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
    Wolf, Douglas C.
    Colombel, Jean Frederic
    Ponich, Terry P.
    Jovanovic, Igor
    Bossuyt, Peter
    Longman, Randy
    Alekseeva, Olga
    Petersen, AnnKatrin
    Chitkara, Denesh
    Marta, Cecilia
    Charles, Lorna
    Rubin, David T.
    Afzali, Anita
    Loftus, Edward V.
    Danese, Silvio
    GASTROENTEROLOGY, 2022, 162 (07) : S969 - S969
  • [34] Cost per clinical outcomes with biologics for the treatment of moderately to severely active ulcerative colitis
    Jansen, J.
    Mody, R.
    Ursan, I.
    Lorenzi, M.
    Patel, H.
    Alberton, M.
    JOURNAL OF CROHNS & COLITIS, 2015, 9 : S239 - S240
  • [35] COST-EFFECTIVENESS OF ADALIMUMAB FOR THE TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN CANADA
    Ghosh, S.
    Desjardins, O.
    Skup, M.
    Wang, S.
    Yang, M.
    Yang, H.
    Qi, C.
    Bao, Y.
    Chao, J.
    VALUE IN HEALTH, 2014, 17 (03) : A37 - A37
  • [36] Trends in Medical Management of Moderately to Severely Active Ulcerative Colitis: A Nationwide Retrospective Analysis
    Yuan, William
    Marwaha, Jayson S.
    Rakowsky, Shana T.
    Palmer, Nathan P.
    Kohane, Isaac S.
    Rubin, David T.
    Brat, Gabriel A.
    Feuerstein, Joseph D.
    INFLAMMATORY BOWEL DISEASES, 2023, 29 (05) : 695 - 704
  • [37] COMPARATIVE EFFICACY AND SAFETY OF OZANIMOD AND USTEKINUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
    Dubinsky, Marla C.
    Betts, Keith
    Eren, Devrim
    Tang, Wenxi
    Yin, Lei
    Gupte-Singh, Komal
    GASTROENTEROLOGY, 2022, 162 (07) : S603 - S603
  • [38] Long-term use of ozanimod in patients with moderately to severely active ulcerative colitis
    Danese, S.
    Colombel, J-F
    Ponich, T.
    Jovanovic, I.
    Bossuyt, P.
    Longman, R.
    Alekseeva, O.
    Petersen, A. K.
    Marta, C.
    Charles, L.
    Sparrow, M.
    Rubin, D. T.
    Afzali, A.
    Loftus, E. V., Jr.
    Wolf, D. C.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022, 37 : 125 - 126
  • [39] Adalimumab for Moderately to Severely Active Ulcerative Colitis: A Systematic Review and Meta-Analysis
    Xinlin Chen
    Jiangtao Hou
    Yujie Yuan
    Chaoyuan Huang
    Tianwen Liu
    Chuanwei Mo
    Haiwen Li
    Bin Chen
    Qian Xu
    Zhengkun Hou
    Weiling He
    Fengbin Liu
    BioDrugs, 2016, 30 : 207 - 217
  • [40] Population pharmacokinetic analysis of etrolizumab in patients with moderately-to-severely active ulcerative colitis
    Moein, Anita
    Lu, Tong
    Jonsson, Siv
    Ribbing, Jakob
    Kassir, Nastya
    Zhang, Wenhui
    Sperinde, Gizette
    Zhang, Rong
    Tang, Meina
    Oh, Young S.
    Bruno, Rene
    Zhu, Rui
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2022, 11 (09): : 1244 - 1255
12345